133 related articles for article (PubMed ID: 11392540)
1. Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undecanes.
Pandey A; Seroogy J; Volkots D; Smyth MS; Rose J; Mehrotra MM; Heath J; Ruhter G; Schotten T; Scarborough RM
Bioorg Med Chem Lett; 2001 May; 11(10):1293-6. PubMed ID: 11392540
[TBL] [Abstract][Full Text] [Related]
2. Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 1: design of potent and specific 3,9-diazaspiro[5.5]undecanes.
Smyth MS; Rose J; Mehrotra MM; Heath J; Ruhter G; Schotten T; Seroogy J; Volkots D; Pandey A; Scarborough RM
Bioorg Med Chem Lett; 2001 May; 11(10):1289-92. PubMed ID: 11392539
[TBL] [Abstract][Full Text] [Related]
3. Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 3: synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes.
Mehrotra MM; Heath JA; Rose JW; Smyth MS; Seroogy J; Volkots DL; Ruhter G; Schotten T; Alaimo L; Park G; Pandey A; Scarborough RM
Bioorg Med Chem Lett; 2002 Apr; 12(7):1103-7. PubMed ID: 11909727
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
Mehrotra MM; Heath JA; Smyth MS; Pandey A; Rose JW; Seroogy JM; Volkots DL; Nannizzi-Alaimo L; Park GL; Lambing JL; Hollenbach SJ; Scarborough RM
J Med Chem; 2004 Apr; 47(8):2037-61. PubMed ID: 15056002
[TBL] [Abstract][Full Text] [Related]
5. Nonpeptide glycoprotein IIb/IIIa inhibitors: substituted quinazolinediones and quinazolinones as potent fibrinogen receptor antagonists.
Liverton NJ; Armstrong DJ; Claremon DA; Remy DC; Baldwin JJ; Lynch RJ; Zhang G; Gould RJ
Bioorg Med Chem Lett; 1998 Mar; 8(5):483-6. PubMed ID: 9871603
[TBL] [Abstract][Full Text] [Related]
6. Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors.
Su T; Naughton MA; Smyth MS; Rose JW; Arfsten AE; McCowan JR; Jakubowski JA; Wyss VL; Ruterbories KJ; Sall DJ; Scarborough RM
J Med Chem; 1997 Dec; 40(26):4308-18. PubMed ID: 9435900
[TBL] [Abstract][Full Text] [Related]
7. Oral antiplatelet efficacy and specificity of a novel nonpeptide platelet GPIIb/IIIa receptor antagonist, DMP 802.
Mousa SA; Olson RE; Bozarth JM; Lorelli W; Forsythe MS; Racanelli A; Gibbs S; Schlingman K; Bozarth T; Kapil R; Wityak J; Sielecki TM; Wexler RR; Thoolen MJ; Slee A; Reilly TM; Anderson PS; Friedman PA
J Cardiovasc Pharmacol; 1998 Aug; 32(2):169-76. PubMed ID: 9700976
[TBL] [Abstract][Full Text] [Related]
8. Platelet glycoprotein IIb/IIIa receptor antagonists derived from isoxazolidines.
Confalone PN; Jin F; Mousa SA
Bioorg Med Chem Lett; 1999 Jan; 9(1):55-8. PubMed ID: 9990456
[TBL] [Abstract][Full Text] [Related]
9. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
Bednar RA; Gaul SL; Hamill TG; Egbertson MS; Shafer JA; Hartman GD; Gould RJ; Bednar B
J Pharmacol Exp Ther; 1998 Jun; 285(3):1317-26. PubMed ID: 9618439
[TBL] [Abstract][Full Text] [Related]
10. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
[TBL] [Abstract][Full Text] [Related]
11. Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.
Sall DJ; Arfsten AE; Bastian JA; Denney ML; Harms CS; McCowan JR; Morin JM; Rose JW; Scarborough RM; Smyth MS; Um SL; Utterback BG; Vasileff RT; Wikel JH; Wyss VL; Jakubowski JA
J Med Chem; 1997 Aug; 40(18):2843-57. PubMed ID: 9288166
[TBL] [Abstract][Full Text] [Related]
12. Discovery of an orally active series of isoxazoline glycoprotein IIb/IIIa antagonists.
Xue CB; Wityak J; Sielecki TM; Pinto DJ; Batt DG; Cain GA; Sworin M; Rockwell AL; Roderick JJ; Wang S; Orwat MJ; Frietze WE; Bostrom LL; Liu J; Higley CA; Rankin FW; Tobin AE; Emmett G; Lalka GK; Sze JY; Di Meo SV; Mousa SA; Thoolen MJ; Racanelli AL; Olson RE
J Med Chem; 1997 Jun; 40(13):2064-84. PubMed ID: 9207948
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and evaluation of 1,4-benzodioxine derivatives as novel platelet aggregation inhibitors.
Xie Z; Zhao L; Ding X; Kong Y; Li Z
Future Med Chem; 2018 Feb; 10(4):367-378. PubMed ID: 29380625
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel platelet fibrinogen receptor antagonists with 2H-1,4-benzoxazine-3(4H)-one scaffold. A systematic study.
Anderluh M; Cesar J; Stefanic P; Kikelj D; Janes D; Murn J; Nadrah K; Tominc M; Addicks E; Giannis A; Stegnar M; Dolenc MS
Eur J Med Chem; 2005 Jan; 40(1):25-49. PubMed ID: 15642407
[TBL] [Abstract][Full Text] [Related]
15. Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.
Askew BC; Bednar RA; Bednar B; Claremon DA; Cook JJ; McIntyre CJ; Hunt CA; Gould RJ; Lynch RJ; Lynch JJ; Gaul SL; Stranieri MT; Sitko GR; Holahan MA; Glass JD; Hamill T; Gorham LM; Prueksaritanont T; Baldwin JJ; Hartman GD
J Med Chem; 1997 Jun; 40(12):1779-88. PubMed ID: 9191954
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist.
Damiano BP; Mitchell JA; Giardino E; Corcoran T; Haertlein BJ; de Garavilla L; Kauffman JA; Hoekstra WJ; Maryanoff BE; Andrade-Gordon P
Thromb Res; 2001 Oct; 104(2):113-26. PubMed ID: 11672755
[TBL] [Abstract][Full Text] [Related]
17. Orally active isoxazoline glycoprotein IIb/IIIa antagonists with extended duration of action.
Olson RE; Sielecki TM; Wityak J; Pinto DJ; Batt DG; Frietze WE; Liu J; Tobin AE; Orwat MJ; Di Meo SV; Houghton GC; Lalka GK; Mousa SA; Racanelli AL; Hausner EA; Kapil RP; Rabel SR; Thoolen MJ; Reilly TM; Anderson PS; Wexler RR
J Med Chem; 1999 Apr; 42(7):1178-92. PubMed ID: 10197962
[TBL] [Abstract][Full Text] [Related]
18. Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs.
Hutchinson JH; Cook JJ; Brashear KM; Breslin MJ; Glass JD; Gould RJ; Halczenko W; Holahan MA; Lynch RJ; Sitko GR; Stranieri MT; Hartman GD
J Med Chem; 1996 Nov; 39(23):4583-91. PubMed ID: 8917647
[TBL] [Abstract][Full Text] [Related]
19. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.
Frelinger AL; Furman MI; Krueger LA; Barnard MR; Michelson AD
Circulation; 2001 Sep; 104(12):1374-9. PubMed ID: 11560852
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
Nannizzi-Alaimo L; Alves VL; Phillips DR
Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
